JPH10175843A - Cosmetic for skin - Google Patents

Cosmetic for skin

Info

Publication number
JPH10175843A
JPH10175843A JP35418496A JP35418496A JPH10175843A JP H10175843 A JPH10175843 A JP H10175843A JP 35418496 A JP35418496 A JP 35418496A JP 35418496 A JP35418496 A JP 35418496A JP H10175843 A JPH10175843 A JP H10175843A
Authority
JP
Japan
Prior art keywords
skin
fatty acid
vitamin
cholesterol ester
cosmetics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP35418496A
Other languages
Japanese (ja)
Inventor
Yumi Tokitsu
由美 時津
Yasushi Sumida
康史 炭田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kanebo Ltd
Original Assignee
Kanebo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanebo Ltd filed Critical Kanebo Ltd
Priority to JP35418496A priority Critical patent/JPH10175843A/en
Publication of JPH10175843A publication Critical patent/JPH10175843A/en
Pending legal-status Critical Current

Links

Landscapes

  • Cosmetics (AREA)

Abstract

PROBLEM TO BE SOLVED: To obtain cosmetics for skin, consisting essentially of a specific cholesterol ester and vitamin E (derivative) and having improving activities of an aged skin such as improving activities on a roughened skin, advancing activities of water-retaining function and activities for making the skin beautiful. SOLUTION: The objective cosmetics consist essentially of (A) a cholesterol ester of an iso form and/or anti-iso form fatty acid of formulas I [(n) is 6-32] and II, and (B) vitamin E and/or vitamin E derivative (e.g. an acetate). The iso form and/or anti-iso form fatty acid derived from a mammal lanolin or vernix caseosa can be used as the iso form and/or anti-iso form fatty acid. The formulating amount of the component A is preferably 0.01-50wt.% and that of the component B is preferably 0.001-10.0wt.% based on the whole amount of the final preparation. The formulation ratio of the components A to B is preferably (0.01:1) to (100:1). The cosmetics can optionally includes sphingolipids, phospholipids, sterols and steroids other than the essential component.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、医薬部外品、化粧
品等に適用される、老化皮膚改善効果(荒れ肌改善効
果、水分保持機能亢進効果、美肌効果等)に優れた皮膚
化粧料に関する。
TECHNICAL FIELD The present invention relates to a skin cosmetic which is applied to quasi-drugs, cosmetics, etc., and has excellent aging skin improving effects (rough skin improving effect, moisture retaining function enhancing effect, beautiful skin effect, etc.).

【0002】[0002]

【従来の技術】老化した皮膚は、柔軟性および弾力性を
失い、皮膚のしわが増大し、乾燥して滑らかさのない荒
れ肌の状態がみられる。これは、角質層の水分保持機能
の低下やバリヤー機能の低下ならびに皮脂分泌量の低下
等に起因すると考えられている。
BACKGROUND OF THE INVENTION Aged skin loses its flexibility and elasticity, has increased skin wrinkles, and has a dry, non-smooth, rough skin condition. This is considered to be due to a decrease in the water retention function and barrier function of the stratum corneum, a decrease in sebum secretion, and the like.

【0003】老化に伴う荒れ肌の状態は、経表皮水分蒸
散量(Transepidermal Water L
oss、以下TWLと略す)を測定することによって知
ることができる。すなわち、皮膚の水分は、真皮の基底
細胞層から表皮の角質層へと外層に向かうにつれて減少
する水分含量の勾配に沿って、常に皮膚内部から外層部
へ移動し、角質層を通じて外部へ蒸散している。このT
WLは主に角質層の緻密な細胞組織からなる防御機能
(バリヤー機能)により制御されており、該TWL値
は、例えば健常な皮膚の正常な状態におけるヒトの前腕
部皮表では0.2〜0.3mg/cm2/hr の範囲、通常は
0.25mg/cm2/hr 程度以下に保持されている。これに
対して、老化皮膚にみられる荒れ肌では、その程度に応
じてTWL値は上記の範囲の上限値もしくはそれより大
きな値を示し、皮膚の水分保持機能が低下していること
が認められる。これらの荒れ肌の場合、角質層の防御機
能による通常の制御限界を超えた状態にあるか、あるい
は該防御機能が衰えていることに由来するものである。
[0003] The state of rough skin due to aging is determined by the transepidermal water loss (Transepidermal Water L).
oss (hereinafter abbreviated as TWL). That is, the water in the skin always moves from the inside of the skin to the outer layer along the gradient of the water content decreasing from the basal cell layer of the dermis to the stratum corneum of the epidermis toward the outer layer, and evaporates to the outside through the stratum corneum. ing. This T
WL is controlled mainly by a protective function (barrier function) composed of a dense cell tissue of the stratum corneum. The TWL value is, for example, 0.2 to 0.2 in a human forearm skin surface in a normal state of healthy skin. It is kept in the range of 0.3 mg / cm 2 / hr, usually about 0.25 mg / cm 2 / hr or less. On the other hand, in the case of rough skin seen in aged skin, the TWL value shows the upper limit of the above range or a value larger than that, depending on the degree thereof, and it is recognized that the moisture retention function of the skin is reduced. In the case of these rough skins, it is due to a state where the normal control limit by the protective function of the stratum corneum has been exceeded or the protective function has deteriorated.

【0004】一方、皮膚の大部分の構造を形成する成分
として、コラーゲンとエラスチンがあり、皮膚の弾力性
と柔軟性を左右しているといわれている。加齢によりこ
れらの可溶性分画が減少し、架橋構造が形成され、弾力
性と柔軟性が低下すると考えられている。また、加齢に
よりコラーゲンの代謝が低下すると共に、皮膚の細胞間
物質であるヒアルロン酸が顕著に減少し、皮膚の水分量
の低下を招く。その結果、老化皮膚は全体的に萎縮して
非薄化した状態になり、柔軟性、弾力性や滑らかさを失
い、荒れた肌となる。
[0004] On the other hand, collagen and elastin are components that form most of the structure of the skin, and are said to affect the elasticity and flexibility of the skin. It is believed that aging decreases these soluble fractions, forms crosslinked structures, and reduces elasticity and flexibility. In addition, the metabolism of collagen decreases with aging, and hyaluronic acid, which is an intercellular substance of the skin, is significantly reduced, leading to a decrease in the water content of the skin. As a result, the aged skin is totally atrophied and non-thinned, loses its flexibility, elasticity and smoothness, and becomes rough skin.

【0005】このような老化皮膚を改善することを期待
して、皮膚の湿疹、炎症、しわ等に有効であるといわれ
ているビタミンEならびにその誘導体が、皮膚の治療、
保護薬および皮膚化粧料に使用されてきた(特開昭61
−40210号公報)。しかし、実用上において、これ
らビタミンE類を含有した皮膚化粧料を皮膚に適用して
も、組織機能を修復または改善し、皮膚が元来保有する
機能を回復して皮膚の老化防止効果に著効を示す程度に
効果を発揮するまでには至らなかった。
[0005] Vitamin E and its derivatives, which are said to be effective for skin eczema, inflammation and wrinkles, are expected to improve such aging skin.
It has been used for protective agents and skin cosmetics (JP-A-61
-40210). However, in practical use, even when these skin cosmetics containing vitamin Es are applied to the skin, the skin function is restored or improved, the function originally possessed by the skin is restored, and the effect of preventing skin aging is remarkably improved. It was not enough to show the effect.

【0006】また、皮膚老化の要因の一つである水分保
持機能の低下を防ぐことを期待して、従来、スフィンゴ
脂質、脂肪酸、コレステロールおよびコレステロールエ
ステル等、角質層に本来存在し、水分保持機能を担って
いる脂質成分を皮膚に適用する方法が提案されている
(特公平4ー57641号公報、特開昭61ー2600
08号公報、特開昭62ー29508号公報)。さら
に、コレステロールエステルの中でも、イソ型脂肪酸お
よび/またはアンテイソ型脂肪酸のコレステロールエス
テルは角質層の水分保持機能を亢進する効果が高いこと
が提案されている(特開昭60ー199809号公
報)。
[0006] In addition, with the expectation of preventing a decrease in the water retention function, which is one of the factors of skin aging, conventionally, sphingolipids, fatty acids, cholesterol, cholesterol esters and the like originally exist in the stratum corneum, A method has been proposed in which a lipid component responsible for the above is applied to the skin (Japanese Patent Publication No. 4-57641, Japanese Patent Application Laid-Open No. 61-2600).
08, JP-A-62-29508). Furthermore, among cholesterol esters, it has been proposed that cholesterol esters of iso-fatty acids and / or anteiso-fatty acids have a high effect of enhancing the water retention function of the stratum corneum (JP-A-60-199809).

【0007】しかし、これらの角質層に本来存在する脂
質を補充するのみでは、一時的には皮膚を健常な状態に
保つことはできても、持続的かつ十分な水分保持機能亢
進効果は得られなかった。
However, by simply supplementing the lipids originally present in the stratum corneum, the skin can be kept in a healthy state temporarily, but a sustained and sufficient effect of enhancing the water retention function can be obtained. Did not.

【0008】[0008]

【発明が解決しようとする課題】本発明の目的は、従来
品の老化皮膚改善効果の不十分さを解消した、高い老化
皮膚改善効果を持つ皮膚化粧料を提供することにある。
SUMMARY OF THE INVENTION An object of the present invention is to provide a skin cosmetic composition having a high aging skin improving effect, which eliminates the insufficient aging skin improving effect of conventional products.

【0009】[0009]

【課題を解決するための手段】本発明者らは、前に述べ
たような実情からみて、鋭意検討した結果、一般式
(1)および一般式(2)で表されるイソ型脂肪酸およ
び/またはアンテイソ型脂肪酸のコレステロールエステ
ル、ならびにビタミンEおよび/またはビタミンE誘導
体を必須成分とする皮膚化粧料が、本目的を達成できる
ことを見いだした。
DISCLOSURE OF THE INVENTION The present inventors have conducted intensive studies in view of the above-mentioned circumstances, and as a result, have found that isoform fatty acids represented by the general formulas (1) and (2) and / or Alternatively, it has been found that a skin cosmetic containing cholesterol ester of anteiso fatty acid and vitamin E and / or a vitamin E derivative as essential components can achieve the object.

【0010】[0010]

【化3】 Embedded image

【0011】(但し、nは6〜32で示される。)(Where n is 6 to 32)

【0012】[0012]

【化4】 Embedded image

【0013】(但し、nは6〜32で示される。)(However, n is represented by 6 to 32)

【0014】[0014]

【発明の実施の形態】BEST MODE FOR CARRYING OUT THE INVENTION

【0015】以下、本発明の実施の形態を詳述する。Hereinafter, embodiments of the present invention will be described in detail.

【0016】従来より化粧品原料として用いられてい
る、イソステアリン酸は分岐位置および分岐アルキル鎖
長は特定されていないが、ほとんどは2−ヘプチルウン
デカン酸を意味する。一方、本発明で開示するイソ型、
アンテイソ型脂肪酸はそれぞれ末端より2位〔前記一般
式(1)〕、および末端より3位〔前記一般式(2)〕
にメチル基を持つ脂肪酸に限定される。分岐位置および
分岐アルキル鎖長が特定されている点で、本発明は、従
来公知原料とは異なる。
[0016] Isostearic acid, which has been conventionally used as a raw material for cosmetics, does not specify the branch position and the branched alkyl chain length, but most means 2-heptylundecanoic acid. On the other hand, isoforms disclosed in the present invention,
The anteiso-type fatty acids are respectively 2-position from the terminal [the above-mentioned general formula (1)] and 3-position from the terminal [the above-mentioned general formula (2)]
Limited to fatty acids having a methyl group. The present invention differs from conventionally known raw materials in that the branch position and the branched alkyl chain length are specified.

【0017】本発明に用いる、分岐脂肪酸コレステロー
ルエステルはイソ型、アンテイソ型に分離する必要はな
いが、分離して用いても良い。また、これらの分岐脂肪
酸コレステロールエステルは他の脂肪酸コレステロール
エステルとの混合物でよいが、分岐脂肪酸コレステロー
ルエステルのみからなるものでもよい。イソ型脂肪酸お
よびアンテイソ型脂肪酸の総炭素数は10〜32が好ま
しく、さらに好ましくは総炭素数12〜28である。
The branched fatty acid cholesterol ester used in the present invention does not need to be separated into an iso form and an ante iso form, but may be used separately. Further, these branched fatty acid cholesterol esters may be a mixture with other fatty acid cholesterol esters, or may be composed of only branched fatty acid cholesterol esters. The total carbon number of the iso fatty acid and the anteiso fatty acid is preferably from 10 to 32, more preferably from 12 to 28.

【0018】本発明で用いるイソ型脂肪酸および/また
はアンテイソ型脂肪酸のコレステロールエステルを含む
ことを特徴とする脂肪酸コレステロールエステル混合物
は、ヒトなどの哺乳類の胎児表皮に存在するものであ
り、これらの胎脂から得たものを用いることができる。
また、ラノリン中にも同様の構造の脂肪酸あるいはその
コレステロールエステルが存在することが知られてお
り、これに由来するものを用いることもできる。さらに
は、これらの構造のものは15ーメチルヘプタデカン酸
(イソ型)のエステル化等の方法によっても得ることが
でき、これら合成品を用いることもできる。
The fatty acid cholesterol ester mixture used in the present invention, which is characterized by containing a cholesterol ester of an iso fatty acid and / or an ante iso fatty acid, is present in the fetal epidermis of mammals such as humans. Can be used.
It is also known that lanolin contains a fatty acid or a cholesterol ester thereof having a similar structure, and those derived therefrom can also be used. Furthermore, those having these structures can be obtained by a method such as esterification of 15-methylheptadecanoic acid (isoform), and these synthetic products can also be used.

【0019】本発明で用いるビタミンEおよび/または
その誘導体は、公知の物質であって、例えば、ビタミン
E、ビタミンEアセテート、ビタミンEニコチネート、
ビタミンEサクシネート、ビタミンEオロテート等が挙
げられる。ビタミンEとは、αートコフェロール、βー
トコフェロール、γートコフェロール、δートコフェロ
ール等あるいはこれらの混合物をいう。本発明では、こ
れらのビタミンE単独で、またはその誘導体との混合物
として用いられる。
The vitamin E and / or a derivative thereof used in the present invention are known substances, for example, vitamin E, vitamin E acetate, vitamin E nicotinate,
Vitamin E succinate, vitamin E orotate and the like can be mentioned. Vitamin E refers to α-tocopherol, β-tocopherol, γ-tocopherol, δ-tocopherol, and the like, or a mixture thereof. In the present invention, these vitamin Es are used alone or as a mixture with a derivative thereof.

【0020】本発明のイソ型脂肪酸および/またはアン
テイソ型脂肪酸のコレステロールエステルの配合量は、
最終製剤の総量を基準として、0.01〜50.0重量
%(以下、wt%と略す)が好ましい。ビタミンEおよ
び/またはその誘導体の配合量は、最終製剤の総量を基
準として、0.001〜10.0wt%が好ましい。ま
た、本発明の脂肪酸コレステロールエステル混合物とビ
タミンEおよび/またはその誘導体の配合比率は0.0
1:1〜100:1が好ましい。
The compounding amount of the cholesterol ester of the iso-fatty acid and / or the anteiso-fatty acid of the present invention is as follows:
It is preferably 0.01 to 50.0% by weight (hereinafter abbreviated as wt%) based on the total amount of the final preparation. The blending amount of vitamin E and / or its derivative is preferably 0.001 to 10.0 wt% based on the total amount of the final preparation. The mixing ratio of the fatty acid cholesterol ester mixture of the present invention to vitamin E and / or a derivative thereof is 0.0
A ratio of 1: 1 to 100: 1 is preferred.

【0021】本発明の効果をさらに向上させるために、
本発明の皮膚化粧料には必須成分の他にもスフィンゴ脂
質類、リン脂質類、ステロール類、ステロイド類を、本
発明を達成する範囲内で適宜配合することができる。
In order to further improve the effects of the present invention,
In addition to the essential components, sphingolipids, phospholipids, sterols, and steroids can be appropriately added to the skin cosmetic of the present invention as long as the present invention is achieved.

【0022】本発明の皮膚化粧料には、必要に応じて油
脂、色素、香料、防腐剤、界面活性剤、顔料、酸化防止
剤等を本発明の目的を達成する範囲内で適宜配合するこ
とができる。
The skin cosmetic of the present invention may optionally contain oils and fats, pigments, fragrances, preservatives, surfactants, pigments, antioxidants, etc., as needed, within the range of achieving the object of the present invention. Can be.

【0023】また、本発明の皮膚化粧料は、例えばクリ
ーム類、乳液類、ローション類、パック類、美容液等に
適用することができる。
The skin cosmetic of the present invention can be applied to, for example, creams, emulsions, lotions, packs, serums and the like.

【0024】[0024]

【実施例】以下、実施例について説明する。なお、実施
例中で使用した脂肪酸コレステロールエステル混合物は
以下の方法によって得たものを用いた。
Embodiments will be described below. The fatty acid cholesterol ester mixture used in the examples was obtained by the following method.

【0025】(ヒト胎脂由来)出産直後の新生児の皮表
より、ガーゼを用いて胎脂をぬぐい取り、このガーゼか
らクロロホルム:メタノール(2:1)にて胎脂を抽出
した。得られた胎脂からヘキサンおよびベンゼンを展開
溶媒としたシリカゲルカラムクロマトグラフィーによっ
て、脂肪酸コレステロールエステル画分を得た。ガスク
ロマトグラフィーによって、この画分には炭素数14〜
26のイソ型脂肪酸コレステロールエステルが約40
%、炭素数15〜25のアンテイソ型脂肪酸コレステロ
ールエステルが約20%含まれていることを確認した。
残部は不飽和脂肪酸コレステロールエステルであった。
これらの混合物を以下の実施例に供した。
(Derived from human vernix) Vernix was wiped off from the skin surface of a newborn baby immediately after childbirth using gauze, and vernix was extracted from the gauze with chloroform: methanol (2: 1). A fatty acid cholesterol ester fraction was obtained from the obtained vernix by silica gel column chromatography using hexane and benzene as a developing solvent. By gas chromatography, this fraction contained 14 to 14 carbon atoms.
26 isoform fatty acid cholesterol esters of about 40
%, Containing about 20% of an anteiso-type fatty acid cholesterol ester having 15 to 25 carbon atoms.
The balance was unsaturated fatty acid cholesterol ester.
These mixtures were subjected to the following examples.

【0026】(ラノリン由来)日本精化(株)のYOF
CO CLE−NHを用いた。YOFCO CLE−N
Hは、羊毛脂を鹸化分解して得られるラノリン脂肪酸
を、常法に従ってコレステロールとエステル化して得ら
れたものである。また、その組成は炭素数12〜30の
イソ型脂肪酸コレステロールエステルが約35%、炭素
数11〜31のアンテイソ型脂肪酸コレステロールエス
テルが約40%含まれており、残部は炭素数12〜30
の直鎖脂肪酸コレステロールエステルである。
(Derived from lanolin) YOF of Nippon Seika Co., Ltd.
CO CLE-NH was used. YOFCO CLE-N
H is obtained by esterifying lanolin fatty acid obtained by saponifying and decomposing wool fat with cholesterol according to a conventional method. Further, the composition contains about 35% of an iso-type fatty acid cholesterol ester having 12 to 30 carbon atoms and about 40% of an anteiso-type fatty acid cholesterol ester having 11 to 31 carbon atoms, and the balance is 12 to 30 carbon atoms.
Is a straight chain fatty acid cholesterol ester.

【0027】(合成品)市販の15−メチルヘプタデカ
ン酸(アンテイソ型)を、常法に従って、コレステロー
ルとエステル化して、15−メチルヘプタデカン酸コレ
ステロールエステルを得た。
(Synthetic product) Commercially available 15-methylheptadecanoic acid (anteiso type) was esterified with cholesterol according to a conventional method to obtain cholesterol ester of 15-methylheptadecanoic acid.

【0028】また、本発明の皮膚化粧料の皮膚老化防止
効果を評価するために用いた、(1)荒れ肌改善効果試
験、(2)保湿効果試験(TWL値低減率)、(3)美
肌効果試験(実用テスト)は下記の通りである。
Further, (1) a rough skin improvement effect test, (2) a moisturizing effect test (TWL value reduction rate), and (3) a beautiful skin effect used for evaluating the skin aging prevention effect of the skin cosmetic composition of the present invention. The test (practical test) is as follows.

【0029】(1)荒れ肌改善効果試験 下脚に荒れ肌を有する中高年被験者20名を対象として
4週間連続塗布効果を調べた。被験者の左側下脚試験部
位に1日1回約1gの試料を塗布し、試験開始前および
終了後の皮膚の状態を表1の判定基準により肉眼判定し
た。なお、右側下脚は試料を塗布せず対照とした。
(1) Test for Improvement of Rough Skin The effect of continuous application for four weeks was examined on 20 middle-aged and elderly subjects with rough skin on the lower leg. Approximately 1 g of a sample was applied to the left lower leg test site of the test subject once a day, and the condition of the skin before and after the test was visually determined according to the criteria shown in Table 1. The lower leg on the right side was used as a control without applying the sample.

【0030】[0030]

【表1】 [Table 1]

【0031】試験前後の試験部位と対照部位の判定結果
を比較し、皮膚乾燥度が2段階以上改善された場合(例
えば、+→−、++→±)を「有効」、1段階改善され
た場合を「やや有効」、変化がなかった場合を「無効」
とした。試験結果は「有効」、「やや有効」となった被
験者の人数で示した。
By comparing the judgment results of the test site and the control site before and after the test, when the degree of dryness of the skin is improved by two or more stages (for example, + → −, ++ → ±), “effective” is improved by one stage. "Slightly valid" for cases, "Disabled" for no change
And The test results were indicated by the number of subjects who became “effective” and “slightly effective”.

【0032】(2)保湿効果試験(TWL値低減率) 前述の、荒れ肌改善効果試験開始前および終了後の被験
者皮膚を対象として、4週間連続塗布前のTWL値、お
よび塗布後のTWL値の低減率(水分保持機能亢進効
果)を下記のように算出して、保湿効果を調べた。
(2) Moisturizing Effect Test (TWL Value Reduction Rate) The TWL values before and after the continuous application for 4 weeks in the test subject skin before and after the start of the rough skin improvement effect test were determined. The reduction rate (water retention function enhancement effect) was calculated as follows, and the moisture retention effect was examined.

【0033】(TWL値の測定法)密閉した皮表上の空
気の一定時間内の温度変化を電気抵抗にて測定する方法
を用いた。すなわち、被験者の皮表を測定用セルで密閉
し、セルに強制乾燥した空気を通気してセル内を乾燥空
気で充分置換した後、乾燥空気の通気を停止してその時
点でのセル内の相対湿度RHs(%)を求め、次いで1
0分間放置して再びセル内の相対湿度RH10(%)を
測定し、この時の湿度変化から下記の式によりTWL値
(mg/cm2/hr)を算出した。 TWL値=〔(RH10−RHs)×Dt×V×6〕/
(S×100) 但し、Dt:測定温度下(t℃)での空気中の飽和水蒸
気の密度mg/l) V :セルの容積(l) S :測定面積(cm2)
(Measurement method of TWL value) A method of measuring a temperature change of air on a closed skin surface within a predetermined time by electric resistance was used. That is, the skin of the subject is sealed with the measuring cell, forced air is passed through the cell to sufficiently replace the inside of the cell with dry air, and then the ventilation of the dry air is stopped and the inside of the cell at that time is stopped. Determine the relative humidity RHs (%), then
After leaving for 0 minutes, the relative humidity RH10 (%) in the cell was measured again, and the TWL value (mg / cm 2 / hr) was calculated from the change in humidity at this time by the following equation. TWL value = [(RH10−RHs) × Dt × V × 6] /
(S × 100) where Dt: density of saturated water vapor in air at measurement temperature (t ° C.) mg / l) V: cell volume (l) S: measurement area (cm 2 )

【0034】(TWL値の低減率)TWL値の低減率
は、試料塗布前後のTWL値、TWLAおよびTWLB
を下記の式に代入して算出した。 TWL値低減率(%)=(1−TWLB/TWLA)×
100 但し、TWLA:試料塗布前のTWL値 TWLB:試料塗布後のTWL値 TWL値の低減率が20%以上の場合を「有効」、低減
率が20%未満の場合を「無効」とした。試料結果は、
20名中の「有効」であった被験者の人数で表示した。
(Reduction rate of TWL value) The reduction rate of the TWL value is determined by the TWL values before and after the sample application, twla and twlb.
Was calculated by substituting into the following equation. TWL value reduction rate (%) = (1−TWLB / TWLA) ×
100, where TWLA: TWL value before sample application TWLB: TWL value after sample application The case where the reduction rate of the TWL value is 20% or more is “valid”, and the case where the reduction rate is less than 20% is “invalid”. Sample results are
The number was shown as the number of subjects who were “valid” out of 20 subjects.

【0035】(3)美肌効果試験(実用テスト) 荒れ肌、小皺、乾燥肌等を訴える女子被験者(35〜5
5才)20名に試料を1日2回(朝・夕)連続3ケ月使
用後の効果を評価した。試験結果は、皮膚の湿潤性、平
滑性、弾力性の各項目に対して、「皮膚に潤いが生じ
た」、「皮膚が滑らかになった」、「皮膚に張りが生じ
た」と回答した人数で示した。
(3) Beautiful skin effect test (practical test) Female subjects complaining of rough skin, fine wrinkles, dry skin, etc. (35-5
The effect of using the sample twice a day (morning / evening) for three consecutive months was evaluated for 20 persons (5 years old). In the test results, for each item of skin wettability, smoothness, and elasticity, the respondents answered that "skin was moistened", "skin became smooth", and "skin became taut" Indicated by the number of people.

【0036】実施例1〜4、比較例1〜5(スキンクリ
ーム) 表2の組成にて、スキンクリームを調製し、前記諸試験
を実施した。
Examples 1 to 4 and Comparative Examples 1 to 5 (Skin Cream) Skin creams were prepared according to the compositions shown in Table 2, and the above-mentioned tests were carried out.

【0037】(1)組成(1) Composition

【0038】[0038]

【表2】 [Table 2]

【0039】スキンクリーム中に配合した本発明の成分
を表3に示す。
Table 3 shows the ingredients of the present invention incorporated into the skin cream.

【0040】[0040]

【表3】 [Table 3]

【0041】(2) 調製法 (C)および(D)成分を(A)成分中に加え、80℃
に加温溶解した後、80℃に予め加温溶解しておいた
(B)成分を加えて混合・撹拌し、さらにホモミキサー
を用いて乳化した。次いで、撹拌しつつ30℃まで冷却
して各スキンクリームを調製した。
(2) Preparation method Components (C) and (D) are added to component (A),
After heating and dissolving, the component (B) previously heated and dissolved at 80 ° C. was added, mixed and stirred, and further emulsified using a homomixer. Next, each skin cream was prepared by cooling to 30 ° C. while stirring.

【0042】(3) 特性 実施例1〜4、比較例1〜5について、前記諸試験を実
施した。その結果を、後記、表6に示す。
(3) Characteristics The tests described above were carried out for Examples 1-4 and Comparative Examples 1-5. The results are shown in Table 6 below.

【0043】実施例5〜8、比較例6〜8(美容液) 表4の組成にて、美容液を調製し、前記諸試験を実施し
た。
Examples 5 to 8, Comparative Examples 6 to 8 (Serum) Serum was prepared according to the composition shown in Table 4, and the above-mentioned tests were carried out.

【0044】(1)組成(1) Composition

【0045】[0045]

【表4】 [Table 4]

【0046】美容液中に配合した本発明の成分を表5に
示す。
Table 5 shows the components of the present invention mixed in the serum.

【0047】[0047]

【表5】 [Table 5]

【0048】(2) 調製法 (C)および(D)成分を(A)成分中に加え、80℃
に加温溶解し、予め80℃に加熱しておいた(B)成分
に添加して混合し、ホモミキサーで分散した。次いで、
撹拌しつつ30℃まで冷却して各美容液を調製した。
(2) Preparation method Components (C) and (D) are added to component (A),
And added to the component (B) which had been heated to 80 ° C. in advance, mixed, and dispersed with a homomixer. Then
Each essence was prepared by cooling to 30 ° C. while stirring.

【0049】(3) 特性 実施例5〜8、比較例6〜8について、前記諸試験を実
施した。その結果を表6に示す。
(3) Characteristics The tests described above were carried out for Examples 5 to 8 and Comparative Examples 6 to 8. Table 6 shows the results.

【0050】[0050]

【表6】 [Table 6]

【0051】表6に示すように、本発明の皮膚化粧料で
ある実施例1〜4のスキンクリームは、比較例1の脂肪
酸コレステロールエステル混合物およびビタミンE類未
配合化粧料、比較例2の脂肪酸コレステロールエステル
混合物未配合化粧料、比較例3のビタミンE類未配合化
粧料、比較例4の直鎖脂肪酸コレステロールエステル配
合化粧料、比較例5の分岐位置・分岐アルキル鎖長が本
発明と異なる脂肪酸コレステロールエステル配合化粧料
と比較して、諸特性の全てに亘って優れていた。また、
各実施例は配合特性においても異常は認められなかっ
た。さらに、本発明の皮膚化粧料である実施例5〜8の
美容液は、比較例6の脂肪酸コレステロールエステル混
合物未配合化粧料、比較例7のビタミンE類未配合化粧
料、比較例8の不飽和脂肪酸コレステロールエステル配
合化粧料に比較して、諸試験の全てに亘って良好なる結
果が認められた。
As shown in Table 6, the skin creams of Examples 1 to 4, which are the skin cosmetics of the present invention, were the cosmetics containing no mixture of fatty acid cholesterol ester and the vitamin Es of Comparative Example 1, and the fatty acids of Comparative Example 2. Cholesterol ester mixture-free cosmetic, Comparative Example 3 vitamin E-free cosmetic, Comparative Example 4 straight-chain fatty acid cholesterol ester-containing cosmetic, Comparative Example 5 branching position / branched alkyl chain length different from that of the present invention Compared to cholesterol ester-containing cosmetics, they were excellent in all of their properties. Also,
In each of the examples, no abnormality was observed in the compounding characteristics. Furthermore, the cosmetics of Examples 5 to 8, which are the skin cosmetics of the present invention, are the cosmetics without the fatty acid cholesterol ester mixture of Comparative Example 6, the cosmetics without the vitamin Es of Comparative Example 7, and the cosmetics of Comparative Example 8. Good results were observed over all of the tests as compared with the cosmetics containing the saturated fatty acid cholesterol ester.

【0052】[0052]

【発明の効果】以上記載のように、本発明の皮膚化粧料
は、皮膚が本来備えている水分保持機能を亢進、維持す
ることによって皮膚を健常な状態に改善あるいは修復し
て、かつ皮膚老化改善作用を持つ優れた皮膚化粧料を提
供することは明らかである。
As described above, the skin cosmetic of the present invention improves or repairs the skin to a healthy state by enhancing and maintaining the water retention function inherent to the skin, and aging the skin. It is clear that it provides an excellent skin cosmetic having an improving effect.

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】 一般式(1) 【化1】 (但し、nは6〜32で示される。)および一般式
(2) 【化2】 (但し、nは6〜32で示される。)で表されるイソ型
脂肪酸および/またはアンテイソ型脂肪酸のコレステロ
ールエステル、ならびにビタミンEおよび/またはその
誘導体を必須成分とすることを特徴とする皮膚化粧料。
1. A compound of the general formula (1) (Where n is 6 to 32) and the general formula (2) (Where n is from 6 to 32) skin cosmetics comprising, as essential components, a cholesterol ester of an iso-form fatty acid and / or anteiso-form fatty acid, and vitamin E and / or a derivative thereof. Fees.
【請求項2】 イソ型脂肪酸および/またはアンテイソ
型脂肪酸がラノリン由来であるコレステロールエステル
である請求項1記載の皮膚化粧料。
2. The skin cosmetic according to claim 1, wherein the iso fatty acid and / or the anteiso fatty acid is a cholesterol ester derived from lanolin.
【請求項3】 イソ型脂肪酸および/またはアンテイソ
型脂肪酸のコレステロールエステルが哺乳類の胎脂由来
である請求項1記載の皮膚化粧料。
3. The skin cosmetic according to claim 1, wherein the cholesterol ester of an iso-fatty acid and / or anteiso-fatty acid is derived from mammalian vernix.
JP35418496A 1996-12-17 1996-12-17 Cosmetic for skin Pending JPH10175843A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP35418496A JPH10175843A (en) 1996-12-17 1996-12-17 Cosmetic for skin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP35418496A JPH10175843A (en) 1996-12-17 1996-12-17 Cosmetic for skin

Publications (1)

Publication Number Publication Date
JPH10175843A true JPH10175843A (en) 1998-06-30

Family

ID=18435859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP35418496A Pending JPH10175843A (en) 1996-12-17 1996-12-17 Cosmetic for skin

Country Status (1)

Country Link
JP (1) JPH10175843A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153209A (en) * 1999-09-28 2000-11-28 The Procter & Gamble Company Article having a transferable breathable skin care composition thereon
JP2001172176A (en) * 1999-10-06 2001-06-26 Sunstar Inc Skin improver
JP2001253816A (en) * 2000-03-13 2001-09-18 Nof Corp Skin cosmetic
JP2001253815A (en) * 2000-03-13 2001-09-18 Nof Corp Skin cosmetic
KR100439595B1 (en) * 2001-05-18 2004-07-12 주식회사 엘지생활건강 Tocopherol-containing Ceramide Liquid Crystal Capsule, Emulsion thereof and Cosmetic comprising the same
JP2007176830A (en) * 2005-12-27 2007-07-12 Pola Chem Ind Inc External preparation for skin, for improving skin barrier function and its production method
KR101458108B1 (en) * 2012-12-28 2014-11-04 주식회사 코리아나화장품 Pseudolipid Complex Mixture and Skin External Composition Comprising Thereof for Improving Skin Barrier Function
KR101495679B1 (en) * 2013-07-12 2015-02-25 주식회사 바이오랜드 Cosmetic composition comprising vernix and/or amnion extract having anti-aging activity

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153209A (en) * 1999-09-28 2000-11-28 The Procter & Gamble Company Article having a transferable breathable skin care composition thereon
JP2001172176A (en) * 1999-10-06 2001-06-26 Sunstar Inc Skin improver
JP2001253816A (en) * 2000-03-13 2001-09-18 Nof Corp Skin cosmetic
JP2001253815A (en) * 2000-03-13 2001-09-18 Nof Corp Skin cosmetic
JP4523109B2 (en) * 2000-03-13 2010-08-11 日油株式会社 Skin cosmetics
KR100439595B1 (en) * 2001-05-18 2004-07-12 주식회사 엘지생활건강 Tocopherol-containing Ceramide Liquid Crystal Capsule, Emulsion thereof and Cosmetic comprising the same
JP2007176830A (en) * 2005-12-27 2007-07-12 Pola Chem Ind Inc External preparation for skin, for improving skin barrier function and its production method
KR101458108B1 (en) * 2012-12-28 2014-11-04 주식회사 코리아나화장품 Pseudolipid Complex Mixture and Skin External Composition Comprising Thereof for Improving Skin Barrier Function
KR101495679B1 (en) * 2013-07-12 2015-02-25 주식회사 바이오랜드 Cosmetic composition comprising vernix and/or amnion extract having anti-aging activity

Similar Documents

Publication Publication Date Title
GB2079179A (en) Cosmetic Composition Based On an Aqueous Dispersion of Small Lipid Spheres
JP3383496B2 (en) Method for producing liquid crystal emulsion and liquid crystal emulsion composition obtained by the method
JP2001500131A (en) Topical compositions and methods for enhancing lipid barrier synthesis
CN110974767A (en) Composition for skin barrier regeneration repair and application thereof
US6284257B1 (en) Cosmetic water emulsion containing at least one vegetable oil
EP0134954B1 (en) Sebum secretion accelerator
JPH10175843A (en) Cosmetic for skin
JP2575737B2 (en) Liquid cosmetics
JP5069841B2 (en) Use of plant sterol esters and triterpene alcohol esters obtained from rice bran
EP0277641A2 (en) Cosmetics
JPH0520410B2 (en)
JP2001010946A (en) Skin cosmetic
KR100263623B1 (en) Moisturing cosmetic compositions
JPH0366604A (en) Dermal cosmetic
JP2511820B2 (en) Skin cosmetics
JP2018184426A (en) Use of alkyl oxazolidinone as cosmetic agent for skin moisture retention and skin moisture retention method
JPS60184005A (en) Cosmetic for preventing aging of skin
JPS6281307A (en) Skin cosmetic
JP4046426B2 (en) Ceramide derivative and skin cosmetic containing the same
JPH01100114A (en) External preparation for skin
JPH082772B2 (en) Sebum secretagogue
US20040166127A1 (en) Skin preparation
KR100858626B1 (en) Cosmetic Composition for Protecting lip Comprising Ceramide and Synthetic Palmitoylpentapeptide as an Active Ingredient
JPS6239511A (en) Cosmetic for preventing aging of skin
JP3666083B2 (en) Skin cosmetics

Legal Events

Date Code Title Description
A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20040120